Trial Profile
Expanded Access (Compassionate Use) of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory Immune Thrombocytopenic Purpura (ITP)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 09 Aug 2018
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Expanded access; Therapeutic Use
- Sponsors Rigel Pharmaceuticals
- 19 Jun 2018 Status changed from recruiting to completed.
- 08 Dec 2017 New trial record